Precipio, Inc.

Precipio, Inc. is a U.S.-based healthcare biotechnology company focused on cancer diagnostics. It develops and commercializes diagnostic products and pathology services through its clinical laboratory operations and product division.

0,2 %

44,5 %

−1,5 %

+29,8 %

1.61

1.36

— Precipio, Inc.
%
Pathology services89% Clinical laboratory testing and diagnostic pathology services performed through the New Haven CLIA lab.
Diagnostic products11% Cancer-focused laboratory products sold directly and through distributors.

Precipio sells to laboratories, pathology practices, and healthcare organizations that need cancer diagnostic testing...

  • Clinical laboratoriesprimary

    Buy diagnostic products and consumables for use in laboratory workflows and testing

  • Pathology practices and providersprimary

    Use pathology services for cancer-related diagnostic interpretation and testing

  • Healthcare distributorssecondary

    Purchase and distribute products to reach laboratory customers nationwide

  • Patients and referring physicianssecondary

    Receive pathology services through the company’s clinical laboratory operations

Precipio is based in the United States and operates primarily through its New Haven, Connecticut clinical laboratory...

  • •Headquartered and operating in the United States
  • •New Haven CLIA laboratory is a core operating site
  • •Primary commercial focus is the U.S. laboratory market
  • •Products may be sold internationally through distributors

Precipio’s strategy is built around using its own clinical laboratory as a development and validation engine for new...

01
Use the clinical lab as a product development platformshort-term

Internal testing and validation reduce development time and improve product fit for real workflows

02
Expand distributor-led product commercializationmedium-term

National distributors extend reach into laboratory customers without building a large direct sales footprint

03
Build cancer diagnostics offerings that address misdiagnosislong-term

The company’s product pipeline is centered on solving diagnostic accuracy problems in oncology

Precipio faces execution risk from dependence on reimbursement, billing operations, and access to capital, which are...

critical

Liquidity and financing dependence

The business needs external funding and revenue growth to support operations and obligations

Scope
Company-wide
Materiality
high
high

Billing and reimbursement disruption

Pathology services depend on third-party billing systems and payer remittances, so interruptions can delay cash collection

Scope
Pathology services
Materiality
high
high

Regulatory and reimbursement risk

Clinical laboratory and diagnostic businesses are sensitive to healthcare regulation and payer policy

Scope
U.S. diagnostics and pathology
Materiality
high
medium

Trade and tariff exposure

Imported goods or supplier inputs may become more expensive under tariff changes

Scope
Laboratory products supply chain
Materiality
medium
medium

Product development and validation risk

New diagnostics require specimens, skilled staff, and successful validation before commercialization

Scope
Pipeline products
Materiality
medium
Revenue recognition and reimbursement adjustments
Affects quarterly service revenue and receivables
Allowance for credit losses
Affects reported net sales
Going concern and liquidity assumptions
Affects financial statement presentation and risk disclosure
Billing-related liabilities and recoveries
Affects other liabilities and cash flow

PRECIGEN, INC.

PGEN · Pharmaceutical Preparations

INOVIO PHARMACEUTICALS, INC.

INO · Pharmaceutical Preparations

Prelude Therapeutics Inc

PRLD · Pharmaceutical Preparations

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

IO Biotech, Inc.

IOBTQ · Pharmaceutical Preparations

VERACYTE, INC.

VCYT · Services-Medical Laboratories

: 29/04/2026